EUVIMEDEUVIMED entdecken
Systematische ÜbersichtOpen Access · CC BY 4.0

The eyes of the beholder: Perceived barriers to successful drug repurposing

Zsuzsanna Ida Petykó iD, Dalma Hosszú iD, Marcell Csanádi iD, Kristóf Gyöngyösi iD, George Dennis Obeng iD, David Ameyaw iD, Tamás István Dóczi iD, Zoltán Kaló iD, Donald C Lo iD, Helene G van der Meer iD, Pan Pantziarka iD, András Inotai iD

British Journal of Pharmacology · 2026-01 · 183 (2) · 219-233

DOI: 10.1111/bph.70243 ↗

Kurz gefasst

Systematische Übersicht in der Zeitschrift British Journal of Pharmacology, online erschienen am 06.11.2025. Verfasst von Zsuzsanna Ida Petykó und 11 weiteren Autor:innen. Beteiligte Einrichtung: Center for Health Technology Assessment, Semmelweis University, Budapest, Hungary. Hauptthemen laut MEDLINE: Drug Repositioning. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 66 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: European Union's Horizon Europe Research & Innovation programme.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Despite tremendous advances in new drug development over recent decades, the medical needs of an ever increasing and ageing global population are still significantly unmet. Drug repurposing (DR)—finding new therapeutic uses for existing medicinal substances and products—offers a promising strategy by potentially reducing development time, costs and risk. However, currently, significant hurdles restrict broader application of DR. This study was conducted within the European Commission funded REMEDi4ALL consortium to systematically identify and analyse the key policy obstacles perceived to be hindering the success of DR. A systematic literature review was conducted using PubMed and Embase, supplemented by grey literature searches and expert interviews within the consortium. The extracted data underwent thematic analysis. A barrier tree was developed and validated through five workshops with 80 experts from seven stakeholder groups. From 4059 hits, 192 were included for data extraction, resulting in the identification of 33 key barriers grouped into nine main themes: perception of off‐patent medicines, business case for on‐patent DR, business case for off‐patent DR, non‐industry‐funded DR, ecosystem for non‐profit or small and medium‐sized enterprise‐driven repurposing, market authorisation, exclusivity rights, health technology assessment and pricing. This comprehensive analysis provides a foundation for prioritizing the main areas for future interventions. Surprisingly, there were considerable differences in how different stakeholders perceived the importance of a number of key barriers. Such multidimensional aspects of DR barriers will need to inform future development of actionable policy recommendations to enhance the DR ecosystem and facilitate broader access to repurposed medicines.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Drug RepositioningHumans

Stichwörter der Autor:innen

barriersdrug repositioningdrug repurposinghealth technology assessmentmarket authorizationoff‐patentpharmaceutical policy

Autor:innen und Institutionen

  • Center for Health Technology Assessment, Semmelweis University, Budapest, Hungary.
  • Center for Pharmacology and Drug Research & Development, Semmelweis University, Budapest, Hungary.
  • Syreon Research Institute, Budapest, Hungary.
  • Institute of Psychology, University of Pécs, Pécs, Hungary.
  • Syreon Research Africa, Accra, Ghana.
  • European Infrastructure for Translational Medicine (EATRIS), Amsterdam, The Netherlands.

ORCID-Profile: Zsuzsanna Ida Petykó, Dalma Hosszú, Marcell Csanádi, Kristóf Gyöngyösi, George Dennis Obeng, David Ameyaw, Tamás István Dóczi, Zoltán Kaló, Donald C Lo, Helene G van der Meer, Pan Pantziarka, András Inotai

Förderung

  • European Union's Horizon Europe Research & Innovation programme

Zitieren

APA

Petykó, Z. I., Hosszú, D., Csanádi, M., Gyöngyösi, K., Obeng, G. D., Ameyaw, D., Dóczi, T. I., Kaló, Z., Lo, D. C., van der Meer, H. G., Pantziarka, P., & Inotai, A. (2026). The eyes of the beholder: Perceived barriers to successful drug repurposing. British Journal of Pharmacology, 183(2), 219-233. https://doi.org/10.1111/bph.70243

Vancouver

Petykó ZI, Hosszú D, Csanádi M, Gyöngyösi K, Obeng GD, Ameyaw D, et al. The eyes of the beholder: Perceived barriers to successful drug repurposing. British Journal of Pharmacology. 2026;183(2):219-233. doi:10.1111/bph.70243

BibTeX
@article{Petyk2026,
  author = {Petykó, Zsuzsanna Ida and Hosszú, Dalma and Csanádi, Marcell and Gyöngyösi, Kristóf and Obeng, George Dennis and Ameyaw, David and Dóczi, Tamás István and Kaló, Zoltán and Lo, Donald C and van der Meer, Helene G and Pantziarka, Pan and Inotai, András},
  title = {The eyes of the beholder: Perceived barriers to successful drug repurposing},
  journal = {British Journal of Pharmacology},
  year = {2026},
  volume = {183},
  number = {2},
  pages = {219--233},
  doi = {10.1111/bph.70243}
}
Kostenlos starten →